Exco InTouch Address mHealth Solutions in Management of Chronic Conditions at 2014 mHealth Summit
Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, will speak in two mHealth Solutions sessions focused on disease management at the annual mHealth Summit on Monday, 8th and Tuesday 9th December 2014. In addition, on Wednesday, 10th December, Tim Davis, the CEO and Founder of Exco InTouch, will participate in the Personal Connected Health Alliance (PCHA)’s thought leadership roundtable discussion focused on driving cross sector collaboration to improve patient care, reporting and outcomes through mobile and connected health.
The mHealth Summit, now 6 years in the making, is firmly established as the largest mobile health event in the world, and will be held 7–11 December 2014 in Washington DC, USA. Tim Davis will address delivering a holistic self-management programme for chronic obstructive pulmonary disease (COPD) in the ‘Condition Management with Mobile and Connected Health’ session and Chris Watson, Product Manager, will examine how to deliver mHealth programmes, from pilot through to production, across borders at the event’s ‘Scaling mHealth’ session.
Tim Davis commented: “We are delighted to be speaking at this year’s mHealth Summit. Disease management is a crucial area of healthcare and mHealth is set to deliver ever more impactful solutions to the complex challenges for treating patients suffering from chronic conditions across the globe. I look forward to showing how applying a holistic self-management approach to mobile-enabled disease management programmes works to improve patient outcomes and, ultimately, their quality of life.”
Chris Watson commented: “Bringing the full benefits of mHealth solutions across multiple geographic boundaries presents unique challenges. The multitude of varying and complex regulations and differing patient requirements for the precise type and form of mobile and digital technology to be applied requires providers to be highly adaptable, to have strong regional knowledge and to be highly compliant. I very much look forward to sharing our experience in this field.”
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.